teaser
Bayer HealthCare and Onyx Pharmaceuticals today announced that results from more than 20 clinical trials evaluating the use of Nexavar (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010, in Milan, Italy.
“It’s been almost five years since the approval of Nexavar in its first indication, advanced kidney cancer, and since that time the continuum of development in other areas has produced clinically significant findings, leading to a second approval in unresectable liver cancer,” said Dimitris Voliotis, vice president, Global Clinical Development Oncology, Bayer HealthCare. “Our dedication to the development of Nexavar is demonstrated by the array of data being presented at this year’s ESMO Congress as well as the ongoing clinical trial program evaluating Nexavar in a variety of treatment settings and patient types.”
Nexavar highlights include:
• First Interim Results of the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) Study
– Riccardo Lencioni, MD, Division of Diagnostic and Interventional Radiology, Cisanello University Hospital, Pisa, Italy
– Poster 827P, Poster Presentation I
– Saturday, October 9, 2010, 1:00 – 2:00 pm CET, Hall 3
• Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models
– Baek-Yeol Ryoo, MD, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
– Poster 828P, Poster Presentation I
– Saturday, October 9, 2010, 1:00 – 2:00 pm CET, Hall 3
• Sorafenib Safety Over Time in >4600 Patients with Renal Cell Carcinoma (RCC): Insights from an Integrated Database of Eight Company-Sponsored Trials
– Tim Eisen, MD, Professor, Cambridge Research Institute, Cambridge, United Kingdom
– Poster 905P, Poster Presentation I
– Saturday, October 9, 2010, 1:00 – 2:00 pm CET, Hall 3
• Sorafenib in Older Patients with Advanced Renal Cell Carcinoma: Subanalysis by Age of an Integrated Database of Eight Company-Sponsored Trials
– Giuseppe Procopio, M.D., Istituto Tumori Milano, Milan, Italy
– Poster 906P, Poster Presentation I
– Saturday, October 9, 2010, 1:00 – 2:00 pm CET, Hall 3
• Sorafenib plus Gemcitabine and Cisplatin (vs Gemcitabine and Cisplatin Alone in the First-Line Treatment of Chemonaive Patients with Stage IIIB (with Effusion)/IV Non-Small Cell Lung Cancer (NSCLC): Phase 3 NSCLC Research Experience Utilizing Sorafenib (NExUS) Trial
– Ulrich Gatzemeier, MD, Head of the Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany
– Late-Breaking Abstract 16, Proffered Paper
– Monday, October 11, 2010, 1:15 – 2:30 pm CET, Gold Hall
• Sorafenib plus Capecitabine in Patients with Triple-Negative Advanced Breast Cancer: Subgroup Analysis of SOLTI-0701, a Double-Blind, Randomised, Placebo-Controlled Phase 2b Study
– Henri Roché, M.D., Professor of Medical Oncology, Institut Claudius Regaud, Toulouse, France
– Poster 300P, Poster Presentation I
– Saturday, October 9, 2010, 1:00 – 2:00 pm CET, Hall 3
